Mga Batayang Estadistika
| LEI | 549300CZOCFHQ2BBTR11 |
| CIK | 1628908 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Evolent Health, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 21, 2025 |
EX-4.1 Exhibit 4.1 EVOLENT HEALTH, INC. AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of August 21, 2025 4.50% Convertible Senior Notes due 2031 TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS Section 1.01. Definitions 1 Section 1.02. References to Interest 13 ARTICLE 2 ISSUE, DESCRIPTION, EXECUTION, REGISTRATION AND EXCHANGE OF NOTES Section 2.01. Designation and A |
|
| August 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 August 18, 2025 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organization) |
|
| August 21, 2025 |
EVOLENT HEALTH, INC. 4.50% Convertible Senior Notes due 2031 Purchase Agreement EX-10.1 Exhibit 10.1 Execution Version EVOLENT HEALTH, INC. 4.50% Convertible Senior Notes due 2031 Purchase Agreement August 18, 2025 Oppenheimer & Co. Inc. As Representative of the several Initial Purchasers listed in Schedule 1 hereto c/o Oppenheimer & Co. Inc. 85 Broad Street New York, New York 10004 Ladies and Gentlemen: Evolent Health, Inc., a Delaware corporation (the “Company”), proposes t |
|
| August 19, 2025 |
EX-99.1 Exhibit 99.1 Evolent Health, Inc. Announces Pricing of Oversubscribed and Upsized $145.0 Million of Convertible Senior Notes Due 2031 to Repurchase Existing Notes and Class A Common Stock WASHINGTON, August 19, 2025 /PRNewswire/ — Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions (“Evolent”), today announced the prici |
|
| August 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 August 18, 2025 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation) (Commission fil |
|
| August 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 August 18, 2025 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation) (Commission fil |
|
| August 18, 2025 |
EX-99.1 Exhibit 99.1 Evolent Health, Inc. Announces Proposed Offering of $140.0 Million of Convertible Senior Notes Due 2031 to Repurchase Existing Notes and Class A Common Stock WASHINGTON, August 18, 2025 /PRNewswire/ — Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions (“Evolent”), today announced that it intends to offer $ |
|
| August 11, 2025 |
Exhibit 10.3 SECOND LIEN CREDIT AGREEMENT by and among EVOLENT HEALTH LLC, as the Borrower, EVOLENT HEALTH, INC., as Parent, Certain Subsidiaries thereof, as Guarantors, The Lenders from Time to Time Party Hereto, and ARES CAPITAL CORPORATION, as Administrative Agent and as Collateral Agent Dated as of August 7, 2025 TABLE OF CONTENTS Page Article I Definitions 1 Section 1.01 Defined Terms 1 Secti |
|
| August 11, 2025 |
Exhibit 10.2 EXCHANGE AGREEMENT This Exchange Agreement (this “Agreement”) is made and entered into as of August 7, 2025 (the “Effective Date”), by and among Evolent Health, Inc., a Delaware corporation, (the “Company”) and each of the undersigned holders of Series A Preferred Stock (as defined below) (each, a “Holder”). RECITALS WHEREAS, at the request of Ares Capital Management LLC, the parties |
|
| August 11, 2025 |
Exhibit 10.1 AMENDMENT NO. 5 TO CREDIT AGREEMENT AMENDMENT NO. 5 to CREDIT AGREEMENT, dated as of June 19, 2025 (this “Amendment”), by the Lenders party hereto, EVOLENT HEALTH LLC, a Delaware limited liability company, as the Administrative Borrower, the other Borrowers party hereto, EVOLENT HEALTH, INC., a Delaware corporation, as the Parent, each other Guarantor party hereto, ARES CAPITAL CORPOR |
|
| August 11, 2025 |
Exhibit 10.6 INTERCREDITOR AGREEMENT by and among ARES CAPITAL CORPORATION, as First Lien Administrative Agent, ACF FINCO I LP, as First Lien Security Agent, and ARES CAPITAL CORPORATION, as Second Lien Administrative Agent and as Second Lien Security Agent Dated as of August 7, 2025 SECTION 1 DEFINITIONS 1.1 Defined Terms 2 1.2 Terms Generally; Timing of Performance; Miscellaneous 14 SECTION 2 LI |
|
| August 11, 2025 |
Exhibit 10.7 AMENDMENT NO. 6 TO CREDIT AGREEMENT AMENDMENT NO. 6 to CREDIT AGREEMENT, dated as of August 7, 2025 (this “Amendment”), by the Lenders party hereto, EVOLENT HEALTH LLC, a Delaware limited liability company, as the Administrative Borrower, the other Borrowers party hereto, EVOLENT HEALTH, INC., a Delaware corporation, as the Parent, each other Guarantor party hereto, ARES CAPITAL CORPO |
|
| August 11, 2025 |
Exhibit 3.1 CERTIFICATE OF ELIMINATION OF CERTIFICATE OF DESIGNATIONS OF THE CUMULATIVE SERIES A CONVERTIBLE PREFERRED SHARES OF EVOLENT HEALTH, INC. PURSUANT TO SECTION 151(g) OF THE GENERAL CORPORATION LAW OF THE STATE OF DELAWARE The undersigned, Seth Blackley, being the Chief Executive Officer of Evolent Health, Inc., a Delaware corporation (the “Company” or “Parent”), does hereby certify that |
|
| August 11, 2025 |
SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) S QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37415 Evolent He |
|
| August 11, 2025 |
Exhibit 10.4 NOTWITHSTANDING ANYTHING HEREIN TO THE CONTRARY, THE LIENS AND SECURITY INTEREST GRANTED TO THE COLLATERAL AGENT PURSUANT TO THIS AGREEMENT IN ANY COLLATERAL AND THE EXERCISE OF ANY RIGHT OR REMEDY BY THE COLLATERAL AGENT WITH RESPECT TO ANY COLLATERAL HEREUNDER ARE SUBJECT TO THE PROVISIONS OF THAT CERTAIN INTERCREDITOR AGREEMENT, DATED AS OF AUGUST 7, 2025 (AS AMENDED, RESTATED, AME |
|
| August 11, 2025 |
Exhibit 10.5 NOTWITHSTANDING ANYTHING HEREIN TO THE CONTRARY, THE LIENS AND SECURITY INTEREST GRANTED TO THE COLLATERAL AGENT PURSUANT TO THIS AGREEMENT IN ANY COLLATERAL AND THE EXERCISE OF ANY RIGHT OR REMEDY BY THE COLLATERAL AGENT WITH RESPECT TO ANY COLLATERAL HEREUNDER ARE SUBJECT TO THE PROVISIONS OF THAT CERTAIN INTERCREDITOR AGREEMENT, DATED AS OF AUGUST 7, 2025 (AS AMENDED, RESTATED, AME |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 August 7, 2025 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organization) |
|
| August 7, 2025 |
Evolent Announces Second Quarter 2025 Results Exhibit 99.1 Evolent Announces Second Quarter 2025 Results WASHINGTON (August 7, 2025) – Evolent Health, Inc. (NYSE: EVH) (“Evolent” or the “Company”), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended June 30, 2025. Seth Bla |
|
| June 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 June 19, 2025 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organization) C |
|
| June 20, 2025 |
Exhibit 99.1 Evolent reiterates Q2 and full year guidance for Adjusted EBITDA Notes accelerating 2026 revenue bookings forecast Secures incremental non-dilutive financing WASHINGTON, June 20, 2025 /PRNewswire/ - Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced that based on leading indicators and paid claims |
|
| June 10, 2025 |
As filed with the Securities and Exchange Commission on June 10, 2025 S-8 As filed with the Securities and Exchange Commission on June 10, 2025 Registration No. |
|
| June 10, 2025 |
Calculation of Filing Fee Table. Calculation of Filing Fee Tables S-8 Evolent Health, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Class A Common Stock, par value $0.01 per share Other 7,126,000 $ 8.05 $ 57,364,300.00 0.0001531 $ 8,782.47 Tota |
|
| June 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 June 5, 2025 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organization) Co |
|
| June 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 June 3, 2025 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organization) Co |
|
| May 9, 2025 |
SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) S QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37415 Evolent H |
|
| May 9, 2025 |
Exhibit 10.2 AMENDED AND RESTATED EVOLENT HEALTH, INC. 2015 OMNIBUS INCENTIVE COMPENSATION PLAN PERFORMANCE STOCK UNIT AWARD AGREEMENT PERFORMANCE STOCK UNIT award agreement under the Amended and Restated EVOLENT HEALTH, INC. 2015 Omnibus Incentive Compensation Plan, dated as of [DATE] between EVOLENT HEALTH, INC., a Delaware corporation (the “Company”), and . This Performance Stock Unit Award Agr |
|
| May 8, 2025 |
Evolent Announces First Quarter 2025 Results Exhibit 99.1 Evolent Announces First Quarter 2025 Results WASHINGTON (May 8, 2025) – Evolent Health, Inc. (NYSE: EVH) (“Evolent” or the “Company”), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended March 31, 2025. Seth Blackl |
|
| May 8, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 May 8, 2025 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organization) Com |
|
| April 25, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| April 25, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 April 16, 2025 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation) Commission File |
|
| April 22, 2025 |
Evolent names Shawn Guertin as new independent nominee for election to its Board of Directors Exhibit 99.1 Evolent names Shawn Guertin as new independent nominee for election to its Board of Directors •Former CFO of CVS Health, Aetna and Coventry Health Care brings deep experience driving growth and profitability. •Mr. Guertin’s nomination represents continuation of Evolent’s board refreshment efforts. WASHINGTON, April 22, 2025 /PRNewswire/ - Evolent Health, Inc. (NYSE: EVH) (“Evolent”), |
|
| February 21, 2025 |
Subsidiaries of Evolent Health, Inc. Exhibit 21.1 List of Subsidiaries Legal Name Jurisdiction of Organization Evolent Health LLC Delaware Evolent Specialty Services, Inc. California EH Holding Company, Inc. Delaware Justify Holdings, Inc. Kentucky Evolent Health International Private Ltd. India Evolent Care Partners Holding Company, Inc. Delaware Evolent Care Partners of Texas, Inc. Texas The Accountable Care Organization Ltd. Michi |
|
| February 21, 2025 |
Insider Trading Policy of Evolent Health, Inc. Exhibit 19 Insider Trading Policy of Evolent Health, Inc. Adopted as of October 26, 2023 All directors, officers and employees of Evolent Health, Inc. and its subsidiaries (collectively, the “Company”), and certain other persons as the Company may determine from time to time (each, a “Covered Individual”) are subject to the provisions of this Insider Trading Policy (this “Policy”). The Company’s B |
|
| February 21, 2025 |
SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) S ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37415 Evolent Health |
|
| February 20, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 February 20, 2025 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organizatio |
|
| February 20, 2025 |
Evolent Announces Fourth Quarter and Full Year 2024 Results Exhibit 99.1 Evolent Announces Fourth Quarter and Full Year 2024 Results •Revenue of $646.5 million for the three months ended December 31, 2024 and $2,554.7 million for the year ended December 31, 2024, representing 16.3% and 30.1% growth over 2023, respectively. •Net loss attributable to common shareholders of Evolent Health, Inc. of $30.6 million for three months ended December 31, 2024 and $93 |
|
| February 14, 2025 |
EX-99.1 2 ex-99-02142025110204.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of February 14, 2025, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United State |
|
| February 10, 2025 |
JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Evolent Health, Inc. |
|
| February 4, 2025 |
Exhibit 99.1 Evolent Health Announces Changes to Board of Directors Richard “Rick” Jelinek to Be Named Chair of the Board at 2025 Annual Meeting Company Continues Board Refreshment Efforts with Brendan Springstubb’s Appointment as New Independent Director WASHINGTON, FEBRUARY 4, 2025 – Evolent Health, Inc. (NYSE: EVH) (“Evolent”), a company focused on achieving better health outcomes for people wi |
|
| February 4, 2025 |
Exhibit 10.1 COOPERATION AGREEMENT This Cooperation Agreement, dated as of February 3, 2025 (this “Agreement”), is by and among Evolent Health, Inc. (the “Company”) and the persons and entities set forth on Exhibit A hereto (the “Engaged Group,” and, for clarity and as applicable, including each member thereof acting individually). RECITALS WHEREAS, the Company and Engaged Capital, LLC, a member o |
|
| February 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 February 3, 2025 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation) Commission Fil |
|
| January 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 January 24, 2025 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation) Commission Fil |
|
| January 13, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 January 13, 2025 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organization |
|
| January 13, 2025 |
EX-99.1 2 evolentjpmpresentationja.htm EX-99.1 Investor Presentation 43rd Annual J.P. Morgan Healthcare Conference January 14, 2025 Disclaimers 2 Certain statements made in this presentation and in other written or oral statements made by us or on our behalf are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”). These include statemen |
|
| December 11, 2024 |
Exhibit 10.1 AMENDMENT NO. 3 TO CREDIT AGREEMENT AMENDMENT NO. 3 to CREDIT AGREEMENT, dated as of December 6, 2024 (this “Amendment”), by the Lenders party hereto, EVOLENT HEALTH LLC, a Delaware limited liability company, as the Administrative Borrower, the other Borrowers party hereto, EVOLENT HEALTH, INC., a Delaware corporation, as the Parent, each other Guarantor party hereto, ARES CAPITAL COR |
|
| December 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 December 6, 2024 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organization |
|
| November 8, 2024 |
SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) S QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37415 Evole |
|
| November 7, 2024 |
Evolent Announces Third Quarter 2024 Results Exhibit 99.1 Evolent Announces Third Quarter 2024 Results •Revenue of $621.4 million, an increase of $110.4 million or 21.6%, from the three months ended September 30, 2023. •Net loss attributable to common shareholders of Evolent Health, Inc. of $(31.2) million and a net loss margin of (5.0)%. •Adjusted EBITDA of $31.8 million resulting in an Adjusted EBITDA margin of 5.1%. •Revises outlook for A |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 November 7, 2024 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organization |
|
| October 17, 2024 |
October 17, 2024 Office of Trade & Services United States Securities and Exchange Commission Division of Corporation Finance 100 F Street N. |
|
| October 4, 2024 |
October 4, 2024 Office of Trade & Services United States Securities and Exchange Commission Division of Corporation Finance 100 F Street N. |
|
| August 9, 2024 |
SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) S QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37415 Evolent He |
|
| August 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 August 8, 2024 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organization) |
|
| August 8, 2024 |
Evolent Announces Second Quarter 2024 Results Exhibit 99.1 Evolent Announces Second Quarter 2024 Results •Revenue of $647.1 million, an increase of $178.0 million or 37.9%, from the three months ended June 30, 2023. •Net loss attributable to common shareholders of Evolent Health, Inc. of $(6.4) million and a net loss margin of (1.0)%. •Adjusted EBITDA of $52.0 million resulting in an Adjusted EBITDA margin of 8.0%. •Narrows revenue outlook fo |
|
| August 7, 2024 |
EX-99 2 Rule13DJointFilingAgreement.htm JOINT FILING AGREEMENT JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Evolent Health, Inc. is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1(k) u |
|
| August 7, 2024 |
EVH / Evolent Health, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Evolent Health, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 30050B101 (CUSIP Number) July 31, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sched |
|
| June 17, 2024 |
EVH / Evolent Health, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment SC 13G 1 tm2417490d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Evolent Health, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 per share (Title of Class of Securities) 30050B101 (CUSIP Number) June 6, 2024 (Date of Event Which Requires Filing of this Statement) Check t |
|
| June 11, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 June 6, 2024 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organization) Co |
|
| June 4, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 June 4, 2024 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organization) Co |
|
| June 4, 2024 |
44th Annual William Blair Growth Stock Conference June 4, 2024 Disclaimers 2 Certain statements made in this presentation and in other written or oral statements made by us or on our behalf are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”). |
|
| June 4, 2024 |
Evolent signs agreement to acquire artificial intelligence utilization management products and team from Machinify •Machinify solution seeks to accelerate the efficiency, quality, and clinical value of Evolent’s specialty condition management platform through AI-enabled clinical workflow automation •Machinify technology leverages the latest advances in applied machine learning, large language models and data analytics •Acquisition expected to benefit health plans, clinicians, and members WASHINGTON, June 4, 2024 - Evolent Health, Inc. |
|
| May 10, 2024 |
SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) S QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37415 Evolent H |
|
| May 10, 2024 |
Exhibit 10.1 EVOLENT HEALTH, INC. 2015 OMNIBUS INCENTIVE COMPENSATION PLAN PERFORMANCE STOCK UNIT AWARD AGREEMENT PERFORMANCE STOCK UNIT award agreement under the EVOLENT HEALTH, INC. 2015 Omnibus Incentive Compensation Plan, dated as of [DATE] between EVOLENT HEALTH, INC., a Delaware corporation (the “Company”), and . This Performance Stock Unit Award Agreement (this “Award Agreement”) sets forth |
|
| May 9, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 May 9, 2024 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organization) Com |
|
| May 9, 2024 |
Evolent Announces First Quarter 2024 Results Exhibit 99.1 Evolent Announces First Quarter 2024 Results •Revenue of $639.7 million, an increase of $212.0 million or 49.6%, from the three months ended March 31, 2023. •Net loss attributable to common shareholders of Evolent Health, Inc. of $(25.2) million and a net loss margin of (3.9)%. •Adjusted EBITDA of $54.1 million resulting in an Adjusted EBITDA margin of 8.5%. •Raises revenue outlook fo |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 26, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 9, 2024 |
EVH / Evolent Health, Inc. / JPMORGAN CHASE & CO - FILING EVOLENT HEALTH, INC. Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 08)* Evolent Health, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 per share (Title of Class of Securities) 30050B101 (CUSIP Number) March 29, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box t |
|
| February 23, 2024 |
As filed with the Securities and Exchange Commission on February 22, 2024 Table of Contents As filed with the Securities and Exchange Commission on February 22, 2024 Registration No. |
|
| February 23, 2024 |
Subsidiaries of Evolent Health, Inc. Exhibit 21.1 List of Subsidiaries Legal Name Jurisdiction of Organization Evolent Health LLC Delaware Evolent Specialty Services, Inc. California Evolent Assurance Solutions, LLC Vermont EH Holding Company, Inc. Delaware Justify Holdings, Inc. Kentucky Evolent Health International Private Ltd. India Evolent Care Partners Holding Company, Inc. Delaware Evolent Care Partners of Texas, Inc. Texas The |
|
| February 23, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-3ASR (Form Type) Evolent Health, Inc. |
|
| February 23, 2024 |
Exhibit 10.13 DEED OF LEASE AGREEMENT BETWEEN 1812 HOLDINGS, LLC, AS LANDLORD, AND EVOLENT HEALTH, LLC AS TENANT DATED DECEMBER 11, 2023 1812 NORTH MOORE STREET ARLINGTON, VIRGINIA BASIC LEASE INFORMATION Lease Date: December 11, 2023 (the “Effective Date”) Landlord: 1812 HOLDINGS, LLC, a Delaware limited liability company Tenant: EVOLENT HEALTH, LLC a Delaware limited liability company Premises: |
|
| February 23, 2024 |
Evolent Health, Inc. Clawback Policy. Exhibit 97 EVOLENT HEALTH, INC. CLAWBACK POLICY Approved by the Board of Directors on October 26, 2023 1.Purpose. The purpose of this Policy is to describe the circumstances in which Executive Officers will be required to repay or return Erroneously Awarded Compensation to members of the Company Group. This Policy is designed to comply with, and will be interpreted in a manner that is consistent w |
|
| February 23, 2024 |
SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) S ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37415 Evolent Health |
|
| February 22, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 February 22, 2024 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organizatio |
|
| February 22, 2024 |
Evolent Announces Fourth Quarter and Full Year 2023 Results Exhibit 99.1 Evolent Announces Fourth Quarter and Full Year 2023 Results •Full year revenue of $1,963.9 million, 45% growth over 2022 •Net loss attributable to common shareholders of Evolent Health, Inc. of $(142.3) million •Adjusted EBITDA of $194.7 million, 84% growth over 2022 •2023 cash flow from operations of $142.6 million •Provides initial outlook for 2024 in line with long-term targets WAS |
|
| February 14, 2024 |
Evolent Adds Russell Glass, Headspace CEO, to Board of Directors Evolent Adds Russell Glass, Headspace CEO, to Board of Directors WASHINGTON, Feb. 14, 2024 /PRNewswire/ - Evolent Health, Inc. (NYSE: EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today appointed Russell Glass to its Board of Directors. Glass has almost 25 years of experience |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 February 12, 2024 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organizatio |
|
| February 13, 2024 |
EVH / Evolent Health, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0889-evolenthealthincclass.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Evolent Health Inc Class A Title of Class of Securities: Common Stock CUSIP Number: 30050B101 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box |
|
| February 8, 2024 |
EVH / Evolent Health, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Evolent Health, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 30050B101 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| January 18, 2024 |
EVH / Evolent Health, Inc. / JPMORGAN CHASE & CO - FILING EVOLENT HEALTH, INC. Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 07)* Evolent Health, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 per share (Title of Class of Securities) 30050B101 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 January 8, 2024 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organization) |
|
| January 8, 2024 |
jpm2024final1924 J.P. Morgan 42nd Annual Healthcare Conference January 9, 2024 Disclaimers 2 Safe Harbor Statement Certain statements, including but not limited to our ability to achieve our financial outlook and targets, and grow our business, made in this presentation are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”). A forward- |
|
| December 11, 2023 |
Exhibit 10.1 EVOLENT HEALTH, INC. 3.50% Convertible Senior Notes due 2029 Purchase Agreement December 5, 2023 Goldman Sachs & Co. LLC Oppenheimer & Co. Inc. As Representatives of the several Initial Purchasers listed in Schedule 1 hereto c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 c/o Oppenheimer & Co. Inc. 85 Broad Street New York, New York 10004 Ladies and Gentlemen: Evo |
|
| December 11, 2023 |
Exhibit 4.1 EVOLENT HEALTH, INC. AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of December 8, 2023 3.50% Convertible Senior Notes due 2029 TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS Section 1.01. Definitions 1 Section 1.02. References to Interest 13 ARTICLE 2 ISSUE, DESCRIPTION, EXECUTION, REGISTRATION AND EXCHANGE OF NOTES Section 2.01. Designation and Amount |
|
| December 11, 2023 |
Exhibit 10.2 AMENDMENT NO. 2 TO CREDIT AGREEMENT AMENDMENT NO. 2 to CREDIT AGREEMENT, dated as of December 5, 2023 (this “Amendment”), by the Lenders party hereto, EVOLENT HEALTH LLC, a Delaware limited liability company, as the Administrative Borrower, the other Borrowers party hereto, EVOLENT HEALTH, INC., a Delaware corporation, as the Parent, ARES CAPITAL CORPORATION, as Administrative Agent, |
|
| December 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 December 5, 2023 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organization |
|
| December 6, 2023 |
Exhibit 99.1 Evolent Health, Inc. Announces Pricing of $350.0 Million of Convertible Senior Notes Due 2029 to Pay Down Senior Term Loan WASHINGTON, December 5, 2023 /PRNewswire/ - Evolent Health, Inc. (NYSE: EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable (“Evolent”), today anno |
|
| December 6, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 December 5, 2023 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organization |
|
| December 5, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 December 5, 2023 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organization |
|
| December 5, 2023 |
Exhibit 99.1 Evolent Health, Inc. Announces Proposed Offering of $350.0 Million of Convertible Senior Notes Due 2029 to Pay Down Senior Term Loan WASHINGTON, December 5, 2023 /PRNewswire/ - Evolent Health, Inc. (NYSE: EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable (“Evolent”), |
|
| November 3, 2023 |
4,375,000 shares Evolent Health, Inc. Class A common stock Filed Pursuant to Rule 424(b)(7) Registration No. 333-266495 Prospectus supplement (To Prospectus dated August 3, 2022) 4,375,000 shares Evolent Health, Inc. Class A common stock This prospectus supplement relates to the resale from time to time of up to 4,375,000 shares of Class A common stock of Evolent Health, Inc., par value $0.01 per share, issuable upon full conversion of the Company’s Cumul |
|
| November 3, 2023 |
Exhibit 107 EX-FILING FEES Calculation of Filing Fee Table Form 424B7 (Form Type) Evolent Health, Inc. |
|
| November 3, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 November 3, 2023 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organization |
|
| November 3, 2023 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS The following unaudited pro forma condensed combined financial statements have been prepared based on the historical consolidated financial statements of Evolent Health, Inc. (“Evolent”, “we”, “the Company”) to give effect to the following transaction (the “Transaction”): On January 20, 2023, Evolent and Evolent Health LLC (“ |
|
| November 3, 2023 |
As filed with the Securities and Exchange Commission on November 2, 2023 As filed with the Securities and Exchange Commission on November 2, 2023 Registration No. |
|
| November 3, 2023 |
8,474,576 shares Evolent Health, Inc. Class A common stock Filed Pursuant to Rule 424(b)(7) Registration No. 333-266495 Prospectus supplement (To Prospectus dated August 3, 2022) 8,474,576 shares Evolent Health, Inc. Class A common stock This prospectus supplement relates to the resale from time to time of up to 8,474,576 shares of Class A common stock of Evolent Health, Inc., par value $0.01 per share, held by the selling stockholders identified in this |
|
| November 3, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 November 2, 2023 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organization |
|
| November 3, 2023 |
Calculation of Filing Fee Table. Exhibit 107 EX-FILING FEES Calculation of Filing Fee Table Form S-8 (Form Type) Evolent Health, Inc. |
|
| November 3, 2023 |
Exhibit 99.1 COMBINED FINANCIAL STATEMENTS MAGELLAN SPECIALTY HEALTH (A Business of Magellan Health, Inc.) December 31, 2022 MAGELLAN SPECIALTY HEALTH (A Business of Magellan Health, Inc.) COMBINED FINANCIAL STATEMENTS Year Ended December 31, 2022 Contents Report of Independent Auditors 1 Audited Financial Statements Combined Balance Sheet 3 Combined Statement of Income 4 Combined Statement of Net |
|
| November 3, 2023 |
Exhibit 107 EX-FILING FEES Calculation of Filing Fee Table Form 424B7 (Form Type) Evolent Health, Inc. |
|
| November 2, 2023 |
SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) S QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37415 Evole |
|
| November 2, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 November 2, 2023 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organization |
|
| November 2, 2023 |
Evolent Announces Third Quarter 2023 Results Exhibit 99.1 Evolent Announces Third Quarter 2023 Results WASHINGTON (November 2, 2023) – Evolent Health, Inc. (NYSE: EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the quarter ended September 30, 2023. Highlights from the third quarter 20 |
|
| October 16, 2023 |
UNAUDITED PRO FORMA COMBINED FINANCIAL STATEMENTS Exhibit 99.2 UNAUDITED PRO FORMA COMBINED FINANCIAL STATEMENTS The following restated unaudited pro forma combined financial statements (“pro forma financial statements”) have been prepared based on the historical consolidated financial statements of Evolent Health, Inc. (“Evolent”, “we”, “the Company”) to give effect to the following transaction (the “Transaction”): On November 17, 2022, Evolent |
|
| October 16, 2023 |
Exhibit 99.1 COMBINED UNAUDITED FINANCIAL STATEMENTS MAGELLAN SPECIALTY HEALTH (A Business of Magellan Health, Inc.) September 30, 2022 MAGELLAN SPECIALTY HEALTH (A Business of Magellan Health, Inc.) COMBINED FINANCIAL STATEMENTS Contents Combined Balance Sheets as of December 31, 2021 and September 30, 2022 (unaudited) 1 Combined Statements of Income (unaudited) 2 Consolidated Statements of Net P |
|
| October 16, 2023 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 January 19, 2023 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organizati |
|
| September 26, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 January 19, 2023 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organizati |
|
| September 26, 2023 |
Exhibit 99.1 COMBINED FINANCIAL STATEMENTS MAGELLAN SPECIALTY HEALTH (A Business of Magellan Health, Inc.) December 31, 2020 and 2021 MAGELLAN SPECIALTY HEALTH (A Business of Magellan Health, Inc.) COMBINED FINANCIAL STATEMENTS Years Ended December 31, 2020 and 2021 Contents Report of Independent Auditors 1 Audited Financial Statements Combined Balance Sheets 3 Combined Statements of Income 4 Comb |
|
| September 26, 2023 |
UNAUDITED PRO FORMA COMBINED FINANCIAL STATEMENTS Exhibit 99.3 UNAUDITED PRO FORMA COMBINED FINANCIAL STATEMENTS The following restated unaudited pro forma combined financial statements (“pro forma financial statements”) have been prepared based on the historical consolidated financial statements of Evolent Health, Inc. (“Evolent”, “we”, “the Company”) to give effect to the following transaction (the “Transaction”): On November 17, 2022, Evolent |
|
| August 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 August 2, 2023 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation |
|
| August 3, 2023 |
SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) S QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37415 Evolent He |
|
| August 2, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 August 2, 2023 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organization) |
|
| August 2, 2023 |
Evolent Announces Second Quarter 2023 Results Exhibit 99.1 Evolent Announces Second Quarter 2023 Results WASHINGTON (August 2, 2023) – Evolent Health, Inc. (NYSE: EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the quarter ended June 30, 2023. Highlights from the second quarter 2023 an |
|
| July 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 July 26, 2023 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organization) C |
|
| July 26, 2023 |
Evolent welcomes Toyin Ajayi to its Board of Directors Dr. Ajayi becomes the ninth independent board member; adds exceptional, relevant expertise as a CEO, physician, entrepreneur and advocate for improving health care quality and cost for underserved populations. WASHINGTON, (July 26, 2023) – Evolent Health Inc. (NYSE: EVH), a health care company that delivers proven value-based specialty care so |
|
| July 5, 2023 |
June 21, 2023 Office of Trade & Services United States Securities and Exchange Commission Division of Corporation Finance 100 F Street N. |
|
| June 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 June 8, 2023 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organization) Co |
|
| May 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 May 23, 2023 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organization) Co |
|
| May 23, 2023 |
exhibit991 $1.95B 2023 Revenue Outlook at Midpoint 39%1 Revenue CAGR Q4 2019 – Q1 2023 $190M1 2023 Adjusted EBITDA Outlook at Midpoint ~110% Revenue Renewal Rate (2022) $50B Cross-Sell Revenue Opportunity out of $150B Specialty TAM ~5,000 FTE’s Including ~300 MDs and ~1,100 Other Clinicians o o o o o o o Performance Suite Technology and Service Suite/Other Business Model Mature1 Flow- Through Marg |
|
| May 4, 2023 |
SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) S QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37415 Evolent H |
|
| May 4, 2023 |
EXHIBIT 10.6 EVOLENT HEALTH, INC. 2015 OMNIBUS INCENTIVE COMPENSATION PLAN AMENDED AND RESTATED PERFORMANCE STOCK UNIT AWARD AGREEMENT PERFORMANCE STOCK UNIT award agreement under the EVOLENT HEALTH, INC. 2015 Omnibus Incentive Compensation Plan, dated as of [DATE] between EVOLENT HEALTH, INC., a Delaware corporation (the “Company”), and . This Performance Stock Unit Award Agreement, as amended an |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 May 3, 2023 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organization) Com |
|
| May 3, 2023 |
Evolent Health Announces First Quarter 2023 Results Exhibit 99.1 Evolent Health Announces First Quarter 2023 Results WASHINGTON (May 3, 2023) – Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced financial results for the quarter ended March 31, 2023. Highlights from the first quarter 2023 announcement include: •Revenue of $427.7 million, an incr |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 28, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 26, 2023 |
EVH / Evolent Health Inc - Class A / MAGELLAN HEALTH INC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Evolent Health, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 per share (Title of Class of Securities) 30050B101 (CUSIP Number) April 6, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| April 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 April 19, 2023 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organization) |
|
| April 19, 2023 |
Exhibit 99.1 Evolent Health Names New Independent Nominee for Election to Board of Directors Richard Jelinek nominated to join the Board; current director David Farner to depart the Board in June 2023, in addition to previously announced departure of Frank Williams. WASHINGTON (April 19, 2023) — Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven specialty clinical solutio |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 March 28, 2023 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organization) |
|
| March 8, 2023 |
EVH / Evolent Health Inc - Class A / UPMC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Evolent Health, Inc. (Name of Issuer) Class A Common Stock, $0.01 par value per share (Title of Class of Securities) 30050B101 (CUSIP Number) February 28, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| February 24, 2023 |
Exhibit 2.5 STOCK AND ASSET PURCHASE AGREEMENT by and among EVOLENT HEALTH, INC., EVOLENT HEALTH LLC, MAGELLAN HEALTH, INC., and MAGELLAN HEALTHCARE, INC. Dated as of November 17, 2022 TABLE OF CONTENTS Page ARTICLE I PURCHASE AND SALE Section 1.1 Acquisition 1 Section 1.2 Closing 1 Section 1.3 Certain Closing Deliveries 2 Section 1.4 Closing Payments and Issuances 4 Section 1.5 First Post-Closing |
|
| February 24, 2023 |
Exhibit 10.28 SEVERANCE AND CHANGE-IN-CONTROL AGREEMENT THIS SEVERANCE AND CHANGE-IN-CONTROL AGREEMENT (this “Agreement”), dated as of January 27, 2021 (the “Effective Date”), is made by and between Evolent Health, Inc., a corporation organized under the laws of the State of Delaware (the “Company”) and Dan McCarthy (“Executive”). WHEREAS, the Board of Directors of the Company (the “Board”) has de |
|
| February 24, 2023 |
SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) S ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37415 Evolent Health |
|
| February 24, 2023 |
Exhibit 2.6 AMENDMENT NO. 1 TO STOCK AND ASSET PURCHASE AGREEMENT This AMENDMENT NO. 1, dated as of January 20, 2023 (this “Amendment”), is by and among Evolent Health, Inc., a Delaware corporation (“Buyer Parent”), Evolent Health LLC, a Delaware limited liability company (“Buyer” and, together with Buyer Parent, the “Buyer Entities”), and Magellan Health, Inc., a Delaware corporation (“Seller Par |
|
| February 24, 2023 |
Exhibit 2.7 AMENDMENT NO. 2 TO STOCK AND ASSET PURCHASE AGREEMENT This AMENDMENT NO. 2, dated as of February 17, 2023 (this “Amendment”), is by and among Evolent Health, Inc., a Delaware corporation (“Buyer Parent”), Evolent Health LLC, a Delaware limited liability company (“Buyer” and, together with Buyer Parent, the “Buyer Entities”), and Magellan Health, Inc., a Delaware corporation (“Seller Pa |
|
| February 24, 2023 |
Subsidiaries of Evolent Health, Inc. Exhibit 21.1 List of Subsidiaries Legal Name Jurisdiction of Organization Evolent Health LLC Delaware NCIS Holdings, Inc. Delaware NCH Management Systems, Inc. California Evolent Assurance Solutions, LLC Vermont EH Holding Company, Inc. Delaware Justify Holdings, Inc. Kentucky Evolent Health International Private Ltd. India Evolent Care Partners Holding Company, Inc. Delaware Evolent Care Partners |
|
| February 22, 2023 |
Evolent Health Announces Fourth Quarter and Full Year 2022 Results Exhibit 99.1 Evolent Health Announces Fourth Quarter and Full Year 2022 Results WASHINGTON (February 22, 2023) – Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced financial results for the quarter ended December 31, 2022. Highlights from the fourth quarter and full year 2022 announcement inclu |
|
| February 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 February 22, 2023 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organizatio |
|
| February 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 February 14, 2023 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organizatio |
|
| February 14, 2023 |
EVH / Evolent Health Inc / GRANAHAN INVESTMENT MANAGEMENT INC/MA Passive Investment SC 13G/A 1 fp0081954-8sc13ga.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 1)* EVOLENT HEALTH, INC (Name of Issuer) Class A Common Stock, par value $0.01 (Title of Class of Securities) 30050B101 (CUS |
|
| February 9, 2023 |
EVH / Evolent Health Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Evolent Health Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 30050B101 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 3, 2023 |
EVH / Evolent Health Inc / UPMC - SC 13G/A Passive Investment SC 13G/A 1 d314073dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Evolent Health, Inc. (Name of Issuer) Class A Common Stock, $0.01 par value per share (Title of Class of Securities) 30050B101 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) |
|
| January 27, 2023 |
EVH / Evolent Health Inc / MAGELLAN HEALTH INC - SC 13G Passive Investment SC 13G 1 brhc10047098sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Evolent Health, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 per share (Title of Class of Securities) 30050B101 (CUSIP Number) January 20, 2023 (Date of Event Which Requires Filing of this Statement) Ch |
|
| January 23, 2023 |
EXHIBIT 3.1 CERTIFICATE OF DESIGNATION OF CUMULATIVE SERIES A CONVERTIBLE PREFERRED SHARES OF EVOLENT HEALTH, INC. Pursuant to Section 151 of the General Corporation Law of the State of Delaware Pursuant to Section 151 of the General Corporation Law of the State of Delaware (the “DGCL”), Evolent Health, Inc., a corporation duly organized and validly existing under the DGCL (the “Company”), in acco |
|
| January 23, 2023 |
EXHIBIT 10.4 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (as may be further amended, modified and supplemented from time to time, this “Agreement”), dated as of January 20, 2023, is by and among Evolent Health, Inc., a Delaware corporation (the “Corporation”), the Stockholders named in Schedule I hereto (each individually, a “Stockholder” and collectively, the “Stockholders”) and a |
|
| January 23, 2023 |
UNAUDITED PRO FORMA COMBINED FINANCIAL STATEMENTS EXHIBIT 99.3 UNAUDITED PRO FORMA COMBINED FINANCIAL STATEMENTS The following unaudited pro forma combined financial statements (“pro forma financial statements”) have been prepared based on the historical consolidated financial statements of Evolent Health, Inc. (“Evolent”, “we”, “the Company”) to give effect to the following transaction (the “Transaction”): On November 17, 2022, Evolent and Evole |
|
| January 23, 2023 |
Exhibit 99.1 COMBINED FINANCIAL STATEMENTS MAGELLAN SPECIALTY HEALTH (A Business of Magellan Health, Inc.) December 31, 2020 and 2021 MAGELLAN SPECIALTY HEALTH (A Business of Magellan Health, Inc.) COMBINED FINANCIAL STATEMENTS Years Ended December 31, 2020 and 2021 Contents Report of Independent Auditors 1 Audited Financial Statements Combined Balance Sheets 3 Combined Statements of Income 4 Cons |
|
| January 23, 2023 |
Exhibit 99.2 COMBINED UNAUDITED FINANCIAL STATEMENTS MAGELLAN SPECIALTY HEALTH (A Business of Magellan Health, Inc.) September 30, 2022 MAGELLAN SPECIALTY HEALTH (A Business of Magellan Health, Inc.) COMBINED FINANCIAL STATEMENTS Contents Combined Balance Sheets as of December 31, 2021 and September 30, 2022 (unaudited) 1 Combined Statements of Income (unaudited) 2 Consolidated Statement of Net Pa |
|
| January 23, 2023 |
EXHIBIT 10.1 AMENDMENT NO. 1 TO CREDIT AGREEMENT AMENDMENT NO. 1 to CREDIT AGREEMENT, dated as of January 20, 2023 (this “Amendment”), by the Lenders party hereto, EVOLENT HEALTH LLC, a Delaware limited liability company, as the Administrative Borrower, the other Borrowers party hereto, EVOLENT HEALTH, INC., a Delaware corporation, as the Parent, each other Guarantor party hereto, Ares Capital Cor |
|
| January 23, 2023 |
EXHIBIT 10.2 SECURITIES PURCHASE AGREEMENT (SERIES A CONVERTIBLE PREFERRED SHARES) BY AND AMONG THE PURCHASERS LISTED ON SCHEDULE I HERETO AND EVOLENT HEALTH, INC. DATED AS OF JANUARY 20, 2023 TABLE OF CONTENTS Page ARTICLE I SALE AND PURCHASE OF SECURITIES 1 Section 1.1 Sale and Purchase of Securities 1 Section 1.2 Closing 2 ARTICLE II REPRESENTATIONS AND WARRANTIES OF THE COMPANY 2 Section 2.1 T |
|
| January 23, 2023 |
EXHIBIT 10.3 INVESTORS RIGHTS AGREEMENT (Series A Convertible Preferred Shares) This INVESTORS RIGHTS AGREEMENT (Series A Convertible Preferred Shares) (this “Agreement”), dated as of January 20, 2023, is made by and among (i) the Purchasers named in Schedule I hereto (collectively, the “Purchasers”), (ii) Evolent Health, Inc., a Delaware corporation (the “Issuer”), and (iii) the Holders who becom |
|
| January 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): January 19, 2023 Evolent Health, Inc. |
|
| January 23, 2023 |
EXHIBIT 10.5 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (as may be further amended, modified and supplemented from time to time, this “Agreement”), dated as of January 20, 2023, is by and among Evolent Health, Inc., a Delaware corporation (the “Corporation”), Magellan Health, Inc., a Delaware corporation (the “Stockholder”) and any other person who may become a party hereto pursua |
|
| January 23, 2023 |
EXHIBIT 10.6 Lock-Up Agreement January 20, 2023 Evolent Health, Inc. 800 N. Glebe Road, Suite 500 Arlington, Virginia 22203 Ladies and Gentlemen: This letter is being delivered to you in connection with the closing of the transactions contemplated by that certain Stock and Asset Purchase Agreement by and among Evolent Health, Inc., a Delaware corporation (“Buyer Parent”), Evolent Health LLC, a Del |
|
| January 20, 2023 |
EVH / Evolent Health Inc / JPMORGAN CHASE & CO - FILING EVOLENT HEALTH, INC. Passive Investment SC 13G/A 1 EvolentHealthInc.htm FILING EVOLENT HEALTH, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 06)* Evolent Health, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 per share (Title of Class of Securities) 30050B101 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Fil |
|
| January 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 January 11, 2023 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organization |
|
| January 11, 2023 |
1 41st Annual J.P. Morgan Healthcare Conference Investor Presentation January 11, 2023 Exhibit 99.1 2 Safe Harbor Statement Certain statements, including but not limited to estimates of Adjusted EBITDA, earnings growth, expected cost synergies and net leverage ratios, made in this presentation and in other written or oral statements made by us or on our behalf are “forward-looking statements” with |
|
| November 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 November 17, 2022 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organizatio |
|
| November 17, 2022 |
1 Acquisition of NIA and Partnership with Centene November 17, 2022 Exhibit 99.1 2 Safe Harbor Statement Certain statements, including but not limited to estimates of Adjusted EBITDA, earnings growth, expected cost synergies and net leverage ratios, made in this presentation and in other written or oral statements made by us or on our behalf are ?forward-looking statements? within the meaning of t |
|
| November 17, 2022 |
EVOLENT HEALTH ANNOUNCES ACQUISITION OF SPECIALTY ASSET NIA AND STRATEGIC PARTNERSHIP WITH CENTENE Exhibit 99.2 EVOLENT HEALTH ANNOUNCES ACQUISITION OF SPECIALTY ASSET NIA AND STRATEGIC PARTNERSHIP WITH CENTENE ?Accelerates Evolent Health's Value-Based Specialty Care Market Leadership ?Transaction Anticipated to be Immediately Accretive to Adjusted EBITDA Margins and Cash Flow ?Highly Complementary Business Expected to Add $85 Million of High-Visibility Adjusted EBITDA by 2024; Maintains Strong |
|
| November 10, 2022 |
Confidential ? Do Not Distribute1 Evolent Health, Inc. Supplemental Investor Presentation November 9, 2022 Exhibit 99.1 2 Safe Harbor Statement Certain statements made in this presentation and in other written or oral statements made by us or on our behalf are ?forward-looking statements? within the meaning of the Private Securities Litigation Reform Act of 1995 (?PSLRA?). A forward-looking statem |
|
| November 10, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 November 9, 2022 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organization |
|
| November 3, 2022 |
SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) S QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37415 Evole |
|
| November 2, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 November 2, 2022 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organization |
|
| November 2, 2022 |
Evolent Health Announces Third Quarter 2022 Results Exhibit 99.1 Evolent Health Announces Third Quarter 2022 Results WASHINGTON (November 2, 2022) ? Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced financial results for the quarter ended September 30, 2022. Highlights from the third quarter of 2022 announcement include: Quarter ended September |
|
| October 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 October 11, 2022 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organization |
|
| September 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 September 1, 2022 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organizatio |
|
| August 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 5)1 Evolent Health, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 per share (Title of Class of Securities) 30050B101 (CUSIP Number) GLENN W. |
|
| August 18, 2022 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 August 17, 2022 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organization) |
|
| August 12, 2022 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 August 11, 2022 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organization) |
|
| August 3, 2022 |
Exhibit 10.3 Execution Version GUARANTEE AGREEMENT GUARANTEE AGREEMENT (this ?Guarantee?), dated as of August 1, 2022, made by each of the signatories hereto (together with any other entity that may become a party hereto as provided herein, the ?Guarantors?), in favor of ARES CAPITAL CORPORATION, a Maryland corporation (?Ares?), as administrative agent for the Lenders (in such capacity, together w |
|
| August 3, 2022 |
3,741,731 shares Evolent Health, Inc. Class A common stock Table of Contents Filed Pursuant to Rule 424(b)(7) Registration No. 333-266495 Prospectus supplement (To Prospectus dated August 3, 2022) 3,741,731 shares Evolent Health, Inc. Class A common stock This prospectus supplement relates to the resale from time to time of up to 3,741,731 shares of Class A common stock of Evolent Health, Inc., par value $0.01 per share, held by the selling stockholders i |
|
| August 3, 2022 |
Exhibit 107 EX-FILING FEES CALCULATION OF FILING FEE TABLE 424B7 (Form Type) Evolent Health, Inc. |
|
| August 3, 2022 |
Exhibit 2.4 AGREEMENT AND PLAN OF MERGER BY AND AMONG EVOLENT HEALTH, INC., EVOLENT HEALTH, LLC, ENDZONE MERGER SUB, INC., TPG GROWTH ICEMAN PARENT, INC. AND THE SELLERS? REPRESENTATIVE DATED AS OF JUNE 24, 2022 TABLE OF CONTENTS LIST OF EXHIBITS AND SCHEDULES 3 AGREEMENT AND PLAN OF MERGER 1 ARTICLE 1 DEFINITIONS 2 1.1 DEFINITIONS 2 1.2 CROSS REFERENCES 17 ARTICLE 2 THE MERGER 20 2.1 THE MERGER 2 |
|
| August 3, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-3ASR (Form Type) Evolent Health, Inc. |
|
| August 3, 2022 |
Exhibit 10.1 EXECUTION VERSION CREDIT AGREEMENT by and among EVOLENT HEALTH LLC, as Administrative Borrower, ENDZONE MERGER SUB, INC., as Initial Borrower which upon consummation of the TPG Acquisition will be merged with and into TPG GROWTH ICEMAN PARENT, INC., as TPG and, upon consummation of the TPG Acquisition, as the survivor thereof, as a Borrower, IMPLANTABLE PROVIDER GROUP, INC., as a Borr |
|
| August 3, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2022 Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 3, 2022 |
As filed with the Securities and Exchange Commission on August 3, 2022 Table of Contents As filed with the Securities and Exchange Commission on August 3, 2022 Registration No. |
|
| August 3, 2022 |
Exhibit 4.1 Execution Version REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?), is dated as of August 1, 2022, by and between Evolent Health, Inc., a Delaware corporation (the ?Company?), TPG Growth V Iceman, L.P., a Delaware limited partnership (the ?TPG Holder?) and the individuals set forth on Schedule I hereto (together with the TPG Holder, each a ?Holder? an |
|
| August 3, 2022 |
Exhibit 10.2 Execution Version SECURITY AGREEMENT SECURITY AGREEMENT, dated as of August 1, 2022, made by each of the signatories hereto (together with any other entity that may become a party hereto as provided herein, the ?Grantors?), in favor of ACF FINCO I LP, a Delaware limited partnership, as collateral agent (in such capacity, together with its successors and assigns in such capacity, the ? |
|
| August 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) S QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37415 Evolent He |
|
| August 2, 2022 |
Evolent Health Announces Second Quarter 2022 Results Announces Four Operating Partner Additions Exhibit 99.1 Evolent Health Announces Second Quarter 2022 Results Announces Four Operating Partner Additions WASHINGTON (August 2, 2022) – Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced financial results for the quarter ended June 30, 2022. Highlights from the second quarter of 2022 announc |
|
| August 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 August 1, 2022 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organization) |
|
| July 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 4)1 Evolent Health, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 per share (Title of Class of Securities) 30050B101 (CUSIP Number) GLENN W. |
|
| June 29, 2022 |
1 Accelerating Evolent?s Market Leadership in Value-Based Care June 29, 2022 2 Safe Harbor Statement Certain statements made in this presentation and in other written or oral statements made by us or on our behalf are ?forward-looking statements? within the meaning of the Private Securities Litigation Reform Act of 1995 (?PSLRA?). |
|
| June 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 June 24, 2022 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organization) C |
|
| June 29, 2022 |
Exhibit 99.2 EVOLENT HEALTH TO ACQUIRE IPG - Expected to Accelerate Evolent Health?s Position as a Leading Provider of Value-Based Specialty Care Solutions - Expands Evolent?s Value-Based Specialty Care Solutions Portfolio to Musculoskeletal Conditions - Expected to be Immediately Accretive to Adjusted EBITDA Margins and Cash Flow - Diversifies Customer Mix and Accelerates Entry into Commercial Li |
|
| June 9, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 June 9, 2022 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organization) Co |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2(a) (Amendment No. 3)1 Evolent Health, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 per share (Title of Class of Securities) 30050B101 (CUSIP Number) GLENN W. |
|
| May 5, 2022 |
Exhibit 10.1 EVOLENT HEALTH, INC. 2015 OMNIBUS INCENTIVE COMPENSATION PLAN PERFORMANCE STOCK UNIT AWARD AGREEMENT PERFORMANCE STOCK UNIT award agreement under the EVOLENT HEALTH, INC. 2015 Omnibus Incentive Compensation Plan, dated as of [DATE] between EVOLENT HEALTH, INC., a Delaware corporation (the ?Company?), and . This Performance Stock Unit Award Agreement (this ?Award Agreement?) sets forth |
|
| May 5, 2022 |
Exhibit 10.2 EVOLENT HEALTH, INC. 2015 OMNIBUS INCENTIVE COMPENSATION PLAN PERFORMANCE STOCK UNIT AWARD AGREEMENT PERFORMANCE STOCK UNIT award agreement under the EVOLENT HEALTH, INC. 2015 Omnibus Incentive Compensation Plan, dated as of [DATE] between EVOLENT HEALTH, INC., a Delaware corporation (the ?Company?), and . This Performance Stock Unit Award Agreement (this ?Award Agreement?) sets forth |
|
| May 5, 2022 |
SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) S QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37415 Evolent H |
|
| May 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 May 4, 2022 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organization) Com |
|
| May 4, 2022 |
Exhibit 99.1 Evolent Health Announces First Quarter 2022 Results Announces Two Operating Partner Additions and One Expansion WASHINGTON (May 4, 2022) ? Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced financial results for the quarter ended March 31, 2022. Highlights from the first quarter of |
|
| April 29, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 March 1, 2022 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organization) C |
|
| February 24, 2022 |
SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) S ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37415 Evolent Health |
|
| February 24, 2022 |
Exhibit 4.6 EVOLENT HEALTH, INC. DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 DESCRIPTION OF COMMON STOCK As of December 31, 2021, Evolent Health, Inc. (the ?Company,? ?us,? ?we,? or ?our?) had one class of securities, our Class A common stock, par value $0.01 per share, registered under Section 12 of the Securities Exchange Ac |
|
| February 24, 2022 |
Subsidiaries of Evolent Health, Inc. Exhibit 21.1 List of Subsidiaries Legal Name Jurisdiction of Organization Evolent Health LLC Delaware NCIS Holdings, Inc. Delaware NCH Management Systems, Inc. California Evolent Assurance Solutions, LLC Vermont EH Holding Company, Inc. Delaware Justify Holdings, Inc. Kentucky Evolent Health International Private Ltd. India Evolent Care Partners Holding Company, Inc. Delaware Evolent Care Partners |
|
| February 24, 2022 |
Exhibit 10.31 RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE EVOLENT HEALTH, INC. 2015 OMNIBUS INCENTIVE COMPENSATION PLAN, dated as of between EVOLENT HEALTH, INC., a Delaware corporation (the ?Company?), and . This Restricted Stock Unit Award Agreement (this ?Award Agreement?) sets forth the terms and conditions of an award of restricted stock units (this ?Award?) that are subject to the terms |
|
| February 23, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 February 23, 2022 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organizatio |
|
| February 23, 2022 |
Exhibit 99.1 Evolent Health Announces Fourth Quarter and Full Year 2021 Results Announces Four New Partner Additions Washington, D.C., (February 23, 2022) ? Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced financial results for the quarter and full year ended December 31, 2021. Highlights fro |
|
| February 14, 2022 |
EVH / Evolent Health Inc / GRANAHAN INVESTMENT MANAGEMENT INC/MA Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 0)* EVOLENT HEALTH, INC (Name of Issuer) Class A Common Stock (Title of Class of Securities) 30050B101 (CUSIP Number) December 31, 2021 (Date of Event Which |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 February 10, 2022 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organizatio |
|
| February 10, 2022 |
EVH / Evolent Health Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Evolent Health Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 30050B101 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| January 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 January 11, 2022 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organization |
|
| January 11, 2022 |
0 40th Annual J.P. Morgan Healthcare Conference Investor Presentation January 12, 2022 1 Safe Harbor Statement Certain statements made in this report and in other written or oral statements made by us or on our behalf are ?forward-looking statements? within the meaning of the Private Securities Litigation Reform Act of 1995 (?PSLRA?). A forward-looking statement is a statement that is not a histor |
|
| January 10, 2022 |
EVH / Evolent Health Inc / JPMORGAN CHASE & CO - FILING EVOLENT HEALTH, INC. Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 05)* Evolent Health, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 per share (Title of Class of Securities) 30050B101 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo |
|
| November 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2(a) (Amendment No. 2)1 Evolent Health, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 per share (Title of Class of Securities) 30050B101 (CUSIP Number) STEVE WOL |
|
| November 4, 2021 |
SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) S QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37415 Evole |
|
| November 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 October 28, 2021 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organization |
|
| November 3, 2021 |
Exhibit 99.2 Evolent Health Elects Dr. Tunde Sotunde MD, MBA, FAAP to Board Of Directors Frank Williams transitions to non-executive Chairman of the Board, as part of Evolent’s thoughtful leadership succession planning process WASHINGTON, November 3, 2021 - Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, to |
|
| November 3, 2021 |
Evolent Health Announces Third Quarter 2021 Results Exhibit 99.1 Evolent Health Announces Third Quarter 2021 Results Washington, D.C., (November 3, 2021) ? Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced financial results for the quarter ended September 30, 2021. Highlights from the third quarter of 2021 announcement include: Quarter ended Se |
|
| October 4, 2021 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 October 1, 2021 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organization) |
|
| August 5, 2021 |
SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) S QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37415 Evolent He |
|
| August 4, 2021 |
Exhibit 2.1 PURCHASE AGREEMENT AND AGREEMENT AND PLAN OF MERGER by and among WINDROSE HEALTH INVESTORS III, L.P., VITAL DECISIONS ACQUISITION, LLC, EVOLENT HEALTH, INC., EVOLENT HEALTH LLC, EV THUNDER MERGER SUB, LLC, and THE REPRESENTATIVE NAMED HEREIN August 2, 2021 TABLE OF CONTENTS Page ARTICLE 1 THE PURCHASE AND THE MERGER 2 1A The Purchase 2 1B The Merger 2 1C Consummation of the Merger 2 1D |
|
| August 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 August 2, 2021 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organization) |
|
| August 4, 2021 |
Evolent Health Announces Second Quarter 2021 Results Exhibit 99.1 Evolent Health Announces Second Quarter 2021 Results Washington, D.C., (August 4, 2021) ? Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced financial results for the quarter ended June 30, 2021. Highlights from the second quarter of 2021 announcement include: Quarter ended June 30 |
|
| August 4, 2021 |
Exhibit 99.2 Evolent Health Announces Agreement to Acquire Vital Decisions, Expanding its Depth and Breadth in Specialty Care Management The addition of Vital Decisions? specialized patient engagement services expected to position New Century Health to accelerate growth, improve patient care quality and increase margins by adding capabilities in patient engagement, telehealth and end-of-life manag |
|
| June 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Registration No. 333- ?????????????????????????????????????????????????? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ?????????????????????????????????????????????????? FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ?????????????????????????????????????????????????? Evolent Health, Inc. (Exact name of registrant as specified in its charter) ???????????? |
|
| June 10, 2021 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF EVOLENT HEALTH, INC. EVOLENT HEALTH, INC. (the ?Corporation?), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the ?DGCL?) does hereby certify as follows: 1.This Certificate of Amendment (the ?Certificate of Amendment?) amends the pro |
|
| June 10, 2021 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 June 10, 2021 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organization) C |
|
| May 21, 2021 |
??????????????????????????????????????? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 13, 2021 |
Confidential ? Do Not Distribute0 Bank of America Conference: Evolent Health May 13, 2021 Exhibit 99. |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 May 13, 2021 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organization) Co |
|
| May 6, 2021 |
Exhibit 10.1 Execution Version STOCK PURCHASE AGREEMENT by and among BRIGHT HEALTH MANAGEMENT, INC., EH HOLDING COMPANY, INC., TRUE HEALTH NEW MEXICO, INC., and SOLELY FOR THE PURPOSE OF SECTION 9.5, Evolent Health LLC Dated as of January 11, 2021 TABLE OF CONTENTS Page ARTICLE I PURCHASE AND SALE 1 Section 1.1 Acquisition 1 Section 1.2 Closing 1 Section 1.3 Certain Closing Deliveries 1 Section 1. |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) S QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37415 Evolent H |
|
| May 6, 2021 |
Exhibit 10.2 EVOLENT HEALTH, INC. 2015 OMNIBUS INCENTIVE COMPENSATION PLAN PERFORMANCE STOCK UNIT AWARD AGREEMENT PERFORMANCE STOCK UNIT award agreement under the EVOLENT HEALTH, INC. 2015 Omnibus Incentive Compensation Plan, dated as of [DATE] between EVOLENT HEALTH, INC., a Delaware corporation (the ?Company?), and . This Performance Stock Unit Award Agreement (this ?Award Agreement?) sets forth |
|
| May 5, 2021 |
Evolent Health Announces First Quarter 2021 Results Exhibit 99.1 Evolent Health Announces First Quarter 2021 Results Washington, D.C., (May 5, 2021) ? Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced financial results for the quarter ended March 31, 2021. Highlights from the first quarter of 2021 announcement include: Quarter ended March 31, 2 |
|
| May 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 May 5, 2021 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organization) Com |
|
| April 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 30, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 21, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| March 31, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 March 31, 2021 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organization) |
|
| February 26, 2021 |
Exhibit 10.32 SEVERANCE AND CHANGE-IN-CONTROL AGREEMENT THIS SEVERANCE AND CHANGE-IN-CONTROL AGREEMENT (this ?Agreement?), dated as of January 27, 2021 (the ?Effective Date?), is made by and between Evolent Health, Inc., a corporation organized under the laws of the State of Delaware (the ?Company?) and Steve Tutewohl (?Executive?). WHEREAS, the Board of Directors of the Company (the ?Board?) has |
|
| February 26, 2021 |
Subsidiaries of Evolent Health, Inc. Exhibit 21.1 List of Subsidiaries Legal Name Jurisdiction of Organization Evolent Health LLC Delaware NCIS Holdings, Inc. Delaware NCH Management Systems, Inc. California Evolent Assurance Solutions, LLC Vermont EH Holding Company, Inc. Delaware True Health New Mexico, Inc. New Mexico Justify Holdings, Inc. Kentucky Juntos Health Plan Inc. Texas Evolent Health International Private Ltd. India Evol |
|
| February 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) S ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37415 Evolent Health |
|
| February 25, 2021 |
Evolent Health Announces Fourth Quarter and Full Year 2020 Results Exhibit 99.1 Evolent Health Announces Fourth Quarter and Full Year 2020 Results Washington, D.C., (February 25, 2021) – Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced financial results for the quarter and full year ended December 31, 2020. Highlights from the fourth quarter and full year 20 |
|
| February 25, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 February 25, 2021 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organizatio |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 February 11, 2021 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organizatio |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Evolent Health Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 30050B101 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| January 29, 2021 |
Exhibit 10.4 SEVERANCE AND CHANGE-IN-CONTROL AGREEMENT THIS SEVERANCE AND CHANGE-IN-CONTROL AGREEMENT (this “Agreement”), dated as of January 27, 2021 (the “Effective Date”), is made by and between Evolent Health, Inc., a corporation organized under the laws of the State of Delaware (the “Company”) and Jonathan Weinberg (“Executive”). WHEREAS, the Board of Directors of the Company (the “Board”) ha |
|
| January 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 December 21, 2020 Date of Report (Date of earliest event reported) Evolent Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37415 32-0454912 (State or other jurisdiction of incorporation or organizat |
|
| January 29, 2021 |
Exhibit 10.1 SEVERANCE AND CHANGE-IN-CONTROL AGREEMENT THIS SEVERANCE AND CHANGE-IN-CONTROL AGREEMENT (this “Agreement”), dated as of January 27, 2021 (the “Effective Date”), is made by and between Evolent Health, Inc., a corporation organized under the laws of the State of Delaware (the “Company”) and Mr. Frank Williams (“Executive”). WHEREAS, the Board of Directors of the Company (the “Board”) h |
|
| January 29, 2021 |
Exhibit 10.3 SEVERANCE AND CHANGE-IN-CONTROL AGREEMENT THIS SEVERANCE AND CHANGE-IN-CONTROL AGREEMENT (this “Agreement”), dated as of January 27, 2021 (the “Effective Date”), is made by and between Evolent Health, Inc., a corporation organized under the laws of the State of Delaware (the “Company”) and John Johnson (“Executive”). WHEREAS, the Board of Directors of the Company (the “Board”) has det |
|
| January 29, 2021 |
Exhibit 10.2 SEVERANCE AND CHANGE-IN-CONTROL AGREEMENT THIS SEVERANCE AND CHANGE-IN-CONTROL AGREEMENT (this “Agreement”), dated as of January 27, 2021 (the “Effective Date”), is made by and between Evolent Health, Inc., a corporation organized under the laws of the State of Delaware (the “Company”) and Mr. Seth Blackley (“Executive”). WHEREAS, the Board of Directors of the Company (the “Board”) ha |
|
| January 22, 2021 |
Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 04)* Evolent Health, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 per share (Title of Class of Securities) 30050B101 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo |
